PTPRC and hematologic disorder: Similarly, epitope editing of CD45 via base editing has rendered HSPCs resistant to CD45-targeted CAR T cells while maintaining CD45 expression and normal hematopoiesis, paving the way for universal CAR T cell therapies against hematologic malignancies [103].